 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Hemosol Inc.
 |
Hemosol Inc. |
 |
 |
 |
NEWS FROM THE WIRES |
 |
Hemosol stock drops on FDA delay of blood trial Aug 14 2001 08:03 AM PDT
> More WIRE STORIES about this company
PROFILE |
 |
Can Hemosol bankrupt blood banks? The biopharmaceutical company is developing Hemolink, a hemoglobin replacement (or blood substitute) used to treat acute anemia caused by chemotherapy or surgery. Hemolink, which is made by purifying, then modifying human red blood cells, obviates the need for donor red blood cell transfusions. Hemosol is conducting trials for the product in Canada, the UK, and the US for cardiac procedures; Hemolink is also being tested for applications relating to orthopedics and cancer. Hemosol is also developing other drugs, including a blood-based treatment for viral diseases of the liver, as well as an anti-oxidant to prevent tissue damage due to reperfusion.
COMPETITION |
 |
BioTime, Inc. (BTX)
Biopure Corporation (BPUR)
Northfield Laboratories Inc. (NFLD)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 0.10
1-Yr. Sales Growth: (93.3)%
Employees: 140
Revenue per employee: $714.29
KEY PEOPLE |
 |
John W. Kennedy
CEO
Lee Hartwell
CFO
CONTACT INFO |
 |
2 Meridian Rd.
Toronto Ontario M9W 4Z7, Canada
Phone: 1-416-798-0700
Fax: 1-416-798-0152
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |